Background and Aims: Antibodies to infliximab reduce serum infliximab with loss of clinical
benefit, but undetectable trough serum concentrations of infliximab may occur without …

Background & Aims The management of inflammatory bowel disease (IBD) poses a particular
challenge during pregnancy because the health of both the mother and the fetus must be …

Background & Aims The medical management of ulcerative colitis (UC) has improved through
the development of new therapies and novel approaches that optimize existing drugs. …

Background & Aims There is controversy regarding the best treatment for patients with
Crohn’s disease because of the lack of direct comparative trials. We compared therapies for …

Background Historically, corticosteroids have been the most commonly used class of
medication for induction of remission in Crohn's disease (CD). Corticosteroids down regulate …

Background Corticosteroids play a key role in the induction of remission in Crohn's disease.
However, corticosteroids can cause significant adverse events. Budesonide is an alternate …

Background Therapeutic drug monitoring ( TDM ) in inflammatory bowel disease ( IBD )
patients receiving anti‐tumour necrosis factor ( TNF ) agents can help optimise outcomes. …

OBJECTIVES: Colectomy rates for ulcerative colitis (UC) have been inconsistently reported.
We assessed temporal trends of colectomy rates for UC, stratified by emergent vs. elective …

OBJECTIVES: Approximately 50% of Crohn’s disease patients undergo an intestinal
resection within 10 years of diagnosis. The risk of second surgery in Crohn’s disease and the …

BACKGROUND & AIMS: There is no reliable standard of disease activity in ulcerative colitis
(UC). We performed a prospective study to systematically compare all non-invasive disease …